Eisai Co Ltd announced that regarding the acquisition of Chinese generic pharmaceutical company
Liaoning TianYi Biological Pharmaceutical Co., Ltd. previously announced on November 27, 2015, the
conditions of transfer have been arranged, including receiving a new
business license from the regulatory authority in China, and the
acquisition has been completed.
The
trading name of Liaoning TianYi Biological Pharmaceutical Co., Ltd.
was changed to “Eisai (Liaoning) Pharmaceutical Co., Ltd.”, and the
company has become a wholly-owned subsidiary of Eisai China Holdings
Ltd.
Through this acquisition, Eisai has entered the generic pharmaceutical
business in China in addition to expanding its existing business focused
on new medicines. By further strengthening its business foundation
established over 25 years of doing business in China and providing a
stable supply of high quality generic pharmaceuticals, Eisai is able to
fulfill an even wider range of medical needs in China. Eisai will
continue to further contribute to increasing the benefits for a greater
number of patients and their families throughout China.
